Journal
SCIENCE CHINA-LIFE SCIENCES
Volume 59, Issue 4, Pages 333-339Publisher
SCIENCE PRESS
DOI: 10.1007/s11427-016-5026-5
Keywords
chimeric antigen receptor; CAR-T cells; guideline; cancer immunotherapy
Categories
Funding
- National High Technology Research and Development Program of China [2014AA020704]
- National Natural and Scientific Foundation of China [81201789/H1611, 81572981/H1611, 81400057/H0111]
Ask authors/readers for more resources
T cells, genetically modified by chimeric antigen receptors (CAR-T), are endowed with specificity to a desired antigen and are cytotoxic to cells expressing the targeted antigen. CAR-T-based cancer immunotherapy is a promising therapy for curing hematological malignancy, such as acute lymphoid leukemia, and is promising for extending their efficacy to defeat solid tumors. To date, dozens of different CAR-T cells have been evaluated in clinical trials to treat tumors; this necessitates the establishment of guidelines for the production and application of CAR-T cells. However, it is challenging to standardize CAR-T cancer therapy because it involves a combination of gene therapy and cell therapy. In this review, we compare the existing guidelines for CAR-T cells and discuss the challenges and considerations for establishing guidance for CAR-T-based cancer immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available